These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 7702421)

  • 1. [Cost-effectiveness analysis of captopril treatment after myocardial infarction].
    Le Pen C; Lévy E; Bonte J
    Arch Mal Coeur Vaiss; 1994 Jun; 87(6):775-81. PubMed ID: 7702421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost effectiveness of captopril after myocardial infarct; comment].
    Szucs T; Berger K; Schulte-Hillen J; Kleber FX
    Med Klin (Munich); 1996 Feb; 91(2):112-8. PubMed ID: 8850108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of captopril therapy after myocardial infarction.
    Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
    J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term mortality in patients with myocardial infarction: impact of early treatment with captopril for 4 weeks.
    Liu L;
    Chin Med J (Engl); 2001 Feb; 114(2):115-8. PubMed ID: 11780187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
    Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
    Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Economic evaluation of the contribution of captopril in the treatment of diabetic nephropathy:a cost-benefit approach].
    Le Pen C; Petitjean P; Lévy P; Hannedouche T
    Nephrologie; 1996; 17(6):321-6. PubMed ID: 8975150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective.
    Pfeffer MA
    Herz; 1993 Dec; 18 Suppl 1():430-5. PubMed ID: 8125423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
    Murcia AM; Hennekens CH; Lamas GA; Jiménez-Navarro M; Rouleau JL; Flaker GC; Goldman S; Skali H; Braunwald E; Pfeffer MA
    Arch Intern Med; 2004 Nov; 164(20):2273-9. PubMed ID: 15534166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study.
    Tokmakova MP; Skali H; Kenchaiah S; Braunwald E; Rouleau JL; Packer M; Chertow GM; Moyé LA; Pfeffer MA; Solomon SD
    Circulation; 2004 Dec; 110(24):3667-73. PubMed ID: 15569840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral captopril versus placebo among 14,962 patients with suspected acute myocardial infarction: a multicenter, randomized, double-blind, placebo controlled clinical trial. Chinese Cardiac Study (CCS-1) Collaborative Group.
    Chin Med J (Engl); 1997 Nov; 110(11):834-8. PubMed ID: 9772413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
    Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G; Solesse A; Beillat M
    Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost effectiveness of ACE inhibition in therapy of chronic heart failure in Switzerland: evaluation based on the SOLVD study].
    Szucs TD; Goedde M; Berger K; Kiowski W
    Schweiz Med Wochenschr; 1997 Jul; 127(29-30):1234-41. PubMed ID: 9333933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
    Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
    Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction.
    Jose P; Skali H; Anavekar N; Tomson C; Krumholz HM; Rouleau JL; Moye L; Pfeffer MA; Solomon SD
    J Am Soc Nephrol; 2006 Oct; 17(10):2886-91. PubMed ID: 16928807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Mark DB; Nelson CL; Anstrom KJ; Al-Khatib SM; Tsiatis AA; Cowper PA; Clapp-Channing NE; Davidson-Ray L; Poole JE; Johnson G; Anderson J; Lee KL; Bardy GH;
    Circulation; 2006 Jul; 114(2):135-42. PubMed ID: 16818817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmyocardial infarction patients: experience from the SAVE trial.
    Connors KF; Lamas GA
    Am J Crit Care; 1995 Jan; 4(1):23-8. PubMed ID: 7894551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.